Follow-Up: Filoviruses research meeting

Strategic agenda for Filoviruses research and monitoring (AFIRM)

Tuesday, 17 May 2022
(14:00-16:00 CET)

Draft Agenda
Objectives of the meeting

The aim of this meeting is to continue discussing the research priorities for filovirus diseases.

These priorities will be embedded in three major action areas, namely:

**ANTICIPATION:** Research Strategies to prevent and control future Filovirus outbreaks.

**REINFORCEMENT:** Research strategies to develop and evaluate additional vaccines.

**CURE:** Foster research to improve standard of care and the development and evaluation of treatments and of post-exposure therapies.
## WHO AFIRM Strategy Roadmap Meeting

### Main Room

**Zoom link:** [https://who-e.zoom.us/meeting/register/tJUtd-GoqTMjHdSTTBu1-k3ft7XfZSxuN2i](https://who-e.zoom.us/meeting/register/tJUtd-GoqTMjHdSTTBu1-k3ft7XfZSxuN2i)

**Password:** AFIRM

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 14:00 – 14:10 | Welcome & Objectives of the meeting  
**Anticipation:** Challenges in filovirus diagnostics and surveillance | César Muñoz-Fontela (BNITM/WHO)   |
| 14:10 – 14:20 | **Reinforcement:** Outlook of filovirus vaccine research  | William Dowling (WHO, CEPI)       |
| 14:20 – 14:30 | **Cure:** Standardization of medical care for filoviral diseases | Simon Funnell (WHO, UKHSA)        |

### Breakout Rooms

### Anticipation

1. What data needs to be collected for prevention of future outbreaks? What kind of analysis models and collaborations do we need to analyze such data?
2. Would it be worthwhile to set up a web-based filovirus surveillance database?
3. Do we have the right diagnostic tools? If not, what tools need to be implemented?
4. What tools do we have in place to prevent relapse and initiation of outbreaks via transmission from survivors?
5. What is the role of domestic animal and wildlife surveillance for outbreak prevention? What is the best strategy?

### Reinforcement

1. What data is missing to allow immunobridging of filovirus vaccines? What is the fastest strategy to acquire such data?
2. Is it possible to develop multivalent virus vaccines?
3. How can we better accelerate the development of vaccines against Marburg and Sudan viruses?
4. Is there a need to boost immunity in survivors?
5. Input on WHO protocol for filovirus vaccine trials.

### Chairs

- César Muñoz-Fontela (BNITM/WHO)
- William Dowling (WHO, CEPI)

**Zoom link:** [https://who.zoom.us/j/94167083987](https://who.zoom.us/j/94167083987)

**Password:** AFIRM_2022
| **Cure** | **Chairs**
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. How can we better share the knowledge gained in previous outbreaks to treat filovirus patients? Is this knowledge translatable to all filovirus diseases? 2. Which interventions improve outcome, in particular preventing multiorgan failure? 3. What post-exposure therapies or combinations thereof are preferred? Do they have prophylactic potential as well? 4. How can we improve collaboration in endemic countries?</td>
<td>Janet Diaz (WHO)  Simon Funnell (WHO, UKHSA)</td>
</tr>
</tbody>
</table>

**Zoom link:** [https://who.zoom.us/j/91726763859](https://who.zoom.us/j/91726763859)
**Password:** AFIRM_2022

---

<table>
<thead>
<tr>
<th><strong>Main Room</strong></th>
<th><strong>15:30 – 16:00</strong>  <strong>Summary or breakout rooms by chairs  Final Remarks and Input</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>16:00</strong></td>
<td><strong>END OF MEETING</strong></td>
</tr>
</tbody>
</table>